Karuna Therapeutics, Inc.
(NASDAQ CM: KRTX)
Rigrodsky Law, P.A. is investigating Karuna Therapeutics, Inc. (“Karuna”) regarding possible breaches of fiduciary duties and other violations of law related to Karuna’s agreement to be acquired by Bristol Myers Squibb. Under the terms of the agreement, Karuna shareholders will receive $330.00 per share in cash.